Economic Evaluation Impact on Patient Access to Medicines and Biotechnology Sector

Abstract

Economic evaluation has been shaping the healthcare industry in recent years and gaining more attention by professionals in the healthcare industry. One of the areas which has been significantly impacted is the pharmaceutical and biotechnology sector. As a result, patients access to innovative and repurposed drugs has also been impacted to the same extent. This article serves to raise awareness and knowledge about the importance of economic evaluation and health technology assessment involved in drug approval process. It uncovers the economic aspect overlooked by many professionals in the healthcare industry. It is also intended for healthcare financial professionals and investment analysts to offer them an insight while drafting equity research and due diligence acquisition reports.